Do glucagon-like peptide-1 receptor agonists (GLP-1’s) reduce the risk of later Parkinson’s disease in type 2 diabetes? Tang and colleagues @FixelInstitute@UFPharmacy take apart this question in a new paper published in the @MDJ_Journal. Do you know where the term ‘let the cat… pic.twitter.com/sznpogiqIX
Teacher, Clinical Supervisor
Clinical Associate Professor, Psychiatry
University of Florida
Affiliation is for identification only. All content and opinions are my own.
View more posts
Gator Psychiatry 